Table 3.

Survival analysis of prognostic factors for overall survival in 20 ATCs^*.

Characteristics	HR	p	95% CI
Gender Men vs. Women	2.27	0.137	(0.77–6.68)
Age (years)	1.01	0.841	(0.94–1.07)
T4 vs. T2/T3	0.43	0.166	(0.13–1.42)
N1 vs. N0	1.57	0.493	(0.43–5.7)
M1 vs. M0	0.87	0.814	(0.27–2.76)
PDL1 Strong vs. Negative and Weak and Moderate	3.88	0.031	(1.13–13.24)
PD1 Positive vs. Negative	0.46	0.187	(0.15–1.45)
TIGIT Positive vs. Negative	1.29	0.635	(0.45–3.66)
LAG3 Positive vs. Negative	1.57	0.387	(0.56–4.36)
VISTA Strong vs. Negative and Weak and Moderate	1.87	0.351	(0.5–6.98)
B7H3 Strong vs. Negative and Weak and Moderate	0.86	0.819	(0.24–3.14)
CTLA4 Moderate and Strong vs. Negative and Weak	0.51	0.298	(0.14–1.81)
BTLA Positive vs. Negative	0.48	0.207	(0.15–1.5)
TIM3 Strong vs. Negative and Weak and Moderate	1.53	0.413	(0.55–4.2)

*Two patients were excluded (one was lost to follow-up and one had followed up in less than 1 month).

The bold values indicates that the p values are less than 0.05, which is considered statistically significant.